Study of GSK3359609 and pembrolizumab in programmed death receptor 1-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma

Trial Identifier:	209229
Sponsor:	GlaxoSmithKline
Collaborator:	Merck Sharp & Dohme Corp.
Start Date:	November 2019
Primary Completion Date:	April 2021
Study Completion Date:	June 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.